A Phase III Study Evaluating the Safety and Efficacy of NEPA, a Fixed-Dose Combination of Netupitant and Palonosetron, for Prevention of Chemotherapy-Induced Nausea and Vomiting Over Repeated Cycles of Chemotherapy